Cabio Biotech (Wuhan) Co., Ltd. (688089) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cabio Biotech (Wuhan) Co., Ltd.

Why is Cabio Biotech (Wuhan) Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 13.78% and Operating profit at 9.56% over the last 5 years

INTEREST(HY) At CNY 0.24 MM has Grown at 7.04%
INTEREST COVERAGE RATIO(Q) Lowest at 27,898.96
CASH AND EQV(HY) Lowest at CNY 361.15 MM

With ROE of 10.11%, it has a fair valuation with a 2.67 Price to Book Value

Over the past year, while the stock has generated a return of 4.19%, its profits have risen by 36.5% ; the PEG ratio of the company is 0.7
At the current price, the company has a high dividend yield of 0.8

Underperformed the market in the last 1 year

The stock has generated a return of 4.19% in the last 1 year, much lower than market (China Shanghai Composite) returns of 14.77%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Cabio Biotech (Wuhan) Co., Ltd. should be less than 10%
Overall Portfolio exposure to Specialty Chemicals should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Cabio Biotech (Wuhan) Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Cabio Biotech (Wuhan) Co., Ltd.

4.19%

1.28

49.80%

China Shanghai Composite

14.77%

1.01

14.58%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.78%

EBIT Growth (5y)

9.56%

EBIT to Interest (avg)

86.76

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

0.33

Tax Ratio

13.92%

Dividend Payout Ratio

27.15%

Pledged Shares

Institutional Holding

ROCE (avg)

10.13%

ROE (avg)

7.71%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.67

EV to EBIT

26.02

EV to EBITDA

18.87

EV to Capital Employed

2.91

EV to Sales

6.93

PEG Ratio

0.72

Dividend Yield

0.78%

ROCE (Latest)

11.17%

ROE (Latest)

10.11%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 167.43 MM

NET SALES(9M)

At CNY 446.56 MM has Grown at 25.19%

ROCE(HY)

Highest at 9.36%

RAW MATERIAL COST(Y)

Fallen by -25.66% (YoY

PRE-TAX PROFIT(Q)

Highest at CNY 56.33 MM

NET PROFIT(Q)

Highest at CNY 48.93 MM

EPS(Q)

Highest at CNY 0.27

-7What is not working for the Company

INTEREST(HY)

At CNY 0.24 MM has Grown at 7.04%

INTEREST COVERAGE RATIO(Q)

Lowest at 27,898.96

CASH AND EQV(HY)

Lowest at CNY 361.15 MM

Here's what is working for Cabio Biotech (Wuhan) Co., Ltd.

Net Sales

At CNY 321.94 MM has Grown at 38.43%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (CNY MM)

Operating Cash Flow

Highest at CNY 167.43 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

Highest at CNY 56.33 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

At CNY 56.33 MM has Grown at 62.33%

over average net sales of the previous four periods of CNY 34.7 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 48.93 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit

At CNY 48.93 MM has Grown at 57.84%

over average net sales of the previous four periods of CNY 31 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.27

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -25.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Cabio Biotech (Wuhan) Co., Ltd.

Interest Coverage Ratio

Lowest at 27,898.96

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest

At CNY 0.24 MM has Grown at 7.04%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Cash and Eqv

Lowest at CNY 361.15 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents